Key result
Heparin has numerous pharmacologic limitations in percutaneous coronary intervention, including variable pharmacokinetics, inability to inhibit clot-bound thrombin, and risk of HIT.
Answers are grounded in this paper and cite their sources.
The text highlights the pharmacologic limitations of heparin in percutaneous coronary intervention, advocating for a modern replacement.
Pharmacologic Limitations of Heparin Dependent on ATlll Nonspecific (indirect mechanism)2 -Binds to plasma proteins (abundant at site of disrupted Percutaneous coronary intervention (PCI) has advanced dramatically since the first procedure was performed. Innovations in technique, better guidewires and balloons, stents, and antiplatelet agents have significantly improved clinical outcomes over the years. Yet, one of the only things that hasn't improved is one of the most important: the primary antithrombin Ciinlcai Implications Highly variable interpatient Nonlinear, dose-dependent response5 pharmacokinetics and a variable half-life' agent used in these procedures. , -Cannot inhibit clot-bound thr~mbin*~~~' Immunogenic2 @parin: outdated and difficult t o use Heparin resistan~e',~ Limited efficacy in acute coronary ~y n d r o m e s ~~~. ~ HIT/HITTSZ 'HemochronB is a registered trademark of International Technidyne Corporation.
No takes yet. Share an insight, caveat, or question.
A 2000 study conducted a review in Percutaneous coronary intervention. Heparin was evaluated. Heparin has numerous pharmacologic limitations in percutaneous coronary intervention, including variable pharmacokinetics, inability to inhibit clot-bound thrombin, and risk of HIT.
Synapse has enriched 10 related papers. Consider them for comparative context: